Printer Friendly

BeiGene's VIDAZA commercially available in China.

M2 EQUITYBITES-February 6, 2018-BeiGene's VIDAZA commercially available in China


BeiGene Ltd's (NASDAQ: BGNE) VIDAZA (azacytidine for injection) is now commercially available in China, the company disclosed on Tuesday.

VIDAZA is a nucleoside metabolic inhibitor that received Chinese approval for patients with Intermediate-2/High-risk myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocyte leukaemia (CMML).

The treatment is marketed in China by BeiGene as a result of an exclusive licence agreement with Celgene Corporation (NASDAQ: CELG).

In a global Phase 3 trial (AZA-001), which involved patients with Intermediate-2 and High-risk MDS, VIDAZA was found to significantly prolong median overall survival to 24.5 months, in comparison to the 15 months observed in the conventional care regimens group.

VIDAZA is recommended in the US by the National Comprehensive Cancer Network (NCCN) Guidelines as a front-line treatment.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:9CHIN
Date:Feb 6, 2018
Previous Article:ANGLE plc and Abbott Laboratories to collaborate on metastatic breast cancer study.
Next Article:Intercontinental Exchange declares record trading week for NYSE FANG+ Index Futures contract.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |